Tamtam Try Tamtam free
Halma plc logo

Halma plc account plan

Innovative safety and health technologies

At a glance

FTSE 100 group of life-saving technology companies in safety, environmental analysis and healthcare, with FY2026 revenue of £2,582.3m.

Halma plc is a FTSE 100 group of "life-saving technology companies" that acquires small to medium-sized businesses in safety, environmental and healthcare niches and grows them under a decentralised model in which each company keeps its brand and board. It operates in more than 20 countries and sells to customers in over 100 countries, from small businesses to OEMs, with the US its largest market at 48% of revenue. In FY2026 (year to 31 March 2026) revenue rose 14.9% to £2,582.3m, with organic growth of 16.6%, and Adjusted EBIT rose 22.2% to £594.5m at a 23.0% margin, its 23rd consecutive year of record Adjusted profit. It has over 9,000 employees and is listed on the London Stock Exchange (LON: HLMA).

Business units

Strategic priorities

Double earnings every five years
Halma aspires to double earnings every five years while keeping high returns; KPIs include organic revenue and profit growth of at least 5%, Adjusted EPS growth of at least 10% and an Adjusted EBIT margin of 19% to 23%.
Acquisitions of niche companies
A record £447m was spent on five acquisitions in FY2026 and a record £515m on six in FY2027 to 24 September 2026, with a healthy pipeline across all three sectors.
Organic investment in R&D
Investing in organic growth is the "number one capital allocation priority": R&D was £122.6m (4.7% of revenue) and capex £56.2m in FY2026.
Scale photonics and diversify
Photonics growth of about 30% is guided for FY2027; management says the constraint is resource rather than capacity, and it is looking at other opportunities to diversify away from the single hyperscaler customer.
Talent and portfolio discipline
Nearly 300 leaders are in development programmes, and Halma will "selectively divest" businesses that no longer fit, such as AAI, Labsphere, Cardios and NovaBone.

Latest results

In its trading update of 24 September 2026, ahead of the half year to 30 September 2026, Halma reported "strong progress in the first half" with broad-based growth and order intake ahead of revenue and of the prior year. It confirmed FY2027 guidance for low double-digit organic constant currency revenue growth, including about five percentage points of photonics premium, and raised Adjusted EBIT margin guidance to 23.5%-24% from around 22.7%. Stronger Sterling is expected to cut FY2027 revenue by about £8m and profit by about £2m. In the prior half year to 30 September 2025, revenue had risen 15.2% to £1,237.4m.

Investments and deals

FY2026 acquisitions
E2S for £226m (its largest ever, December 2025), Brownline for €146m, Safetec for €74m and two healthcare bolt-ons, for £447m in total.
FY2027 acquisitions
Dreampath Diagnostics (€279m), Pyxis water quality monitoring ($200m), Näslund Medical ($45m), itemedical (€23m), Surgistar (US$90m) and DCR Inspection Systems, for a record £515m.
Disposals
Three disposals realised about £83m, including Labsphere, Cardios and NovaBone for $56m in August 2026.
R&D and capex
Organic investment of £179m in FY2026 (R&D £122.6m, capex £56.2m), with FY2027 capex guided at £55m to £60m.

Challenges and risks

Customer concentration in photonics
One hyperscaler customer was 20% of Group revenue in FY2026, under a PO-based relationship with six to twelve months of visibility and no contract.
Economic and geopolitical uncertainty
Halma cites continued economic, geopolitical and market uncertainty, US project delays in Fire Safety and Infrastructure & Asset Safety, and supply chain, inflation and currency effects.
Cyber and IT interruption
Cyber is a "top priority" for the Board, and emerging risks include the pace of AI-driven change and tighter data and AI regulation.
Scaling resources for photonics
Management says the photonics limit is "probably more on the resource front" and requires an entire supply ecosystem to keep scaling.
Acquisition integration
Acquisitions and Portfolio Management is a principal risk as deal volume reaches record levels, with more spending on M&A integration.

What leadership says

“Our Sustainable Growth Model enables us to invest with confidence and deliver compounding growth over the long term.”

Marc Ronchetti, Group Chief Executive · Annual Report and Accounts 2026, June 2026

“our objective is to continue our track record of compounding at a double-digit rate over the long term”

Marc Ronchetti, Group Chief Executive · Full Year Results 2025/26 analysts' presentation, 11 June 2026

“This balanced performance combined with over £600m of investment underpins our ability to deliver sustained compounding growth and strong returns over the long term.”

Carole Cran, Chief Financial Officer · Annual Report and Accounts 2026, June 2026

“It's PO-based, we've got sort of six to twelve months of visibility, but fundamentally, there's not a contract in place”

Marc Ronchetti, Group Chief Executive · Half Year Results 2025/26 analysts' presentation, 20 November 2025, on the hyperscaler customer

Where a supplier can help

Photonics supply chain and talent
The photonics scaling priority is resource-constrained, opening doors for component suppliers, contract manufacturing, engineering recruitment and supply chain partners.
M&A sourcing and integration
Record acquisition activity and added M&A teams create demand for deal sourcing data, due diligence and post-merger integration services.
Group cyber and AI capabilities
Central spending on cyber security and AI, and the Board's cyber priority, suit security and AI vendors able to serve a decentralised group of companies.
R&D tooling for operating companies
Bottom-up R&D of £122.6m across many companies is an opening for engineering software, testing and product development services sold company by company.
Healthcare diagnostics and clinical data
New diagnostics and clinical data acquisitions such as Dreampath and itemedical create needs for integration, interoperability and regulatory support.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Halma plc?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Halma plc

What does Halma do?

Halma is a group of life-saving technology companies in three sectors: Environmental & Analysis, Safety and Healthcare. It acquires companies in specialist niches and grows them with a decentralised model.

What is Halma's revenue?

FY2026 (year to 31 March 2026) revenue was £2,582.3m, up 14.9%, with Adjusted EBIT of £594.5m.

How many employees does Halma have?

Halma has over 9,000 employees in more than 20 countries.

Who leads Halma?

Marc Ronchetti has been Group Chief Executive since April 2023, Carole Cran is CFO since April 2025, and Dame Louise Makin is Chair.

What is Halma's strategy?

Halma aims to double earnings every five years by investing in organic growth, acquiring purpose-aligned small to medium-sized companies and paying a progressive dividend.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)